What is Zymeworks?
Founded in 2003 and headquartered in Vancouver, BC, Zymeworks is dedicated to advancing the field of biotherapeutics through innovative research and development. The company's focus on creating multifunctional biologics positions it at the forefront of therapeutic innovation, aiming to address complex medical needs. Its strategic capital raises, including major enterprise-level investments, reflect a robust growth trajectory and a commitment to scaling its operations and pipeline.
How much funding has Zymeworks raised?
Zymeworks has raised a total of $819.8M across 13 funding rounds:
Multiple Rounds
$22.3M
Multiple Rounds
$34.4M
Series A
$61.5M
Stock Offering
$63.6M
Stock Offering
$97.8M
Stock Offering
$201.3M
Stock Offering
$320.8M
Unspecified (2014): $1M supported by Undisclosed
Share Placement (2014): $17.3M featuring Undisclosed
Corporate Investment (2014): $4M backed by Fonds de Solidarité FTQ
Unspecified (2015): $8.6M with participation from Undisclosed
Unspecified (2015): $24M led by Undisclosed
Unspecified (2015): $1.8M supported by Undisclosed
Series A (2016): $61.5M featuring CTI Life Sciences Fund, Celgene, Eli Lilly & Company, Brace Pharma Capital, Perceptive Advisors, Fonds de Solidarité FTQ, Teralys Capital, Northleaf Venture Catalyst Fund, BDC Capital, Lumira Capital, and Merlin Nexus
Stock Issuance/Offering (2017): $63.6M backed by Undisclosed
Stock Issuance/Offering (2018): $97.8M with participation from Undisclosed
Stock Issuance/Offering (2019): $201.3M led by Undisclosed
Stock Issuance/Offering (2020): $320.8M supported by Undisclosed
Key Investors in Zymeworks
CTI Life Sciences Fund
CTI Life Sciences Fund is a prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies. With over 20 years in business, the firm has made more than 30 investments across various therapeutic modalities, emphasizing both long-term value creation and expedited exit strategies.
Celgene
Celgene was a global biopharmaceutical company that developed innovative therapies for cancer and inflammatory diseases. Acquired by Bristol Myers Squibb in 2019, its investments often targeted companies with promising drug candidates in oncology and immunology.
Brace Pharma Capital
Brace Pharma Capital is an investment firm focused on innovative therapies for diseases that have significant unmet medical needs and limited treatment options. The company seeks to invest in life-changing medicines that can improve patient outcomes.
What's next for Zymeworks?
With a significant financial foundation, Zymeworks is poised for continued expansion and advancement of its therapeutic candidates. The substantial enterprise-level funding suggests a strategic focus on late-stage clinical development, regulatory approvals, and potential commercialization efforts. Future investments will likely be directed towards expanding its research capabilities, forging strategic partnerships, and navigating the complex path to bringing novel treatments to patients worldwide. The company's ability to attract major strategic investments highlights its strong market position and the perceived value of its innovative platform.
See full Zymeworks company page
